[go: up one dir, main page]

DK2013175T5 - p38 Map-kinase-inhibitorer - Google Patents

p38 Map-kinase-inhibitorer Download PDF

Info

Publication number
DK2013175T5
DK2013175T5 DK07732629.6T DK07732629T DK2013175T5 DK 2013175 T5 DK2013175 T5 DK 2013175T5 DK 07732629 T DK07732629 T DK 07732629T DK 2013175 T5 DK2013175 T5 DK 2013175T5
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
map kinase
map
inhibitors
kinase
Prior art date
Application number
DK07732629.6T
Other languages
English (en)
Other versions
DK2013175T3 (da
Inventor
David Charles Festus Moffat
Stéphane Pintat
Stephen Davies
Original Assignee
Macrophage Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608855A external-priority patent/GB0608855D0/en
Priority claimed from GB0613914A external-priority patent/GB0613914D0/en
Application filed by Macrophage Pharma Ltd filed Critical Macrophage Pharma Ltd
Application granted granted Critical
Publication of DK2013175T3 publication Critical patent/DK2013175T3/da
Publication of DK2013175T5 publication Critical patent/DK2013175T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07732629.6T 2006-05-04 2007-05-01 p38 Map-kinase-inhibitorer DK2013175T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0608855A GB0608855D0 (en) 2006-05-04 2006-05-04 Inhibitors of MAP kinase enzymes
GB0613914A GB0613914D0 (en) 2006-07-13 2006-07-13 Inhibitors of p38 map kinase
PCT/GB2007/001596 WO2007129040A1 (en) 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
DK2013175T3 DK2013175T3 (da) 2017-02-20
DK2013175T5 true DK2013175T5 (da) 2020-12-21

Family

ID=38268953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07732629.6T DK2013175T5 (da) 2006-05-04 2007-05-01 p38 Map-kinase-inhibitorer

Country Status (15)

Country Link
US (1) US8044211B2 (da)
EP (1) EP2013175B9 (da)
JP (1) JP5340918B2 (da)
KR (1) KR101429780B1 (da)
CN (1) CN102942520B (da)
AU (1) AU2007246869B2 (da)
BR (1) BRPI0711310B8 (da)
CA (1) CA2650970C (da)
CY (1) CY1118518T1 (da)
DK (1) DK2013175T5 (da)
ES (1) ES2605727T3 (da)
HU (1) HUE033281T2 (da)
NZ (1) NZ573348A (da)
PT (1) PT2013175T (da)
WO (1) WO2007129040A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008053131A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
NZ581942A (en) 2007-06-27 2012-01-12 Astrazeneca Ab Pyrazinone derivatives and their use in the treatment of lung diseases
WO2009060160A1 (en) * 2007-11-07 2009-05-14 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
WO2009106844A1 (en) * 2008-02-29 2009-09-03 Chroma Therapeutics Ltd. Inhibitors of p38 map kinase
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102164536B1 (ko) * 2012-10-17 2020-10-12 매크로파지 파마 리미티드 터트-부틸 n-[2-{4-[6-아미노-5-(2,4-디플루오로벤조일)-2-옥소피리딘-1(2h)-일]-3,5-디플루오로페닐}에틸)-l-알라니네이트 또는 이의 염, 수화물 또는 용매화물
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046999A1 (en) * 2002-03-14 2006-03-02 Cristina Alonso-Alija Monocyclic aroylpyridinones as antiinflammatory agents
PL1877098T3 (pl) * 2005-05-05 2013-09-30 Glaxosmithkline Ip Dev Ltd Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy
WO2009106844A1 (en) * 2008-02-29 2009-09-03 Chroma Therapeutics Ltd. Inhibitors of p38 map kinase

Also Published As

Publication number Publication date
CA2650970A1 (en) 2007-11-15
CN102942520B (zh) 2015-03-04
KR20090014187A (ko) 2009-02-06
CY1118518T1 (el) 2017-07-12
EP2013175B1 (en) 2016-11-09
AU2007246869A1 (en) 2007-11-15
ES2605727T9 (es) 2020-12-11
ES2605727T3 (es) 2017-03-16
WO2007129040A1 (en) 2007-11-15
US20090099185A1 (en) 2009-04-16
EP2013175A1 (en) 2009-01-14
KR101429780B1 (ko) 2014-08-18
HUE033281T2 (en) 2017-11-28
BRPI0711310B8 (pt) 2021-05-25
CA2650970C (en) 2014-09-16
NZ573348A (en) 2012-01-12
AU2007246869B2 (en) 2012-10-18
EP2013175B9 (en) 2020-11-11
JP5340918B2 (ja) 2013-11-13
DK2013175T3 (da) 2017-02-20
US8044211B2 (en) 2011-10-25
PT2013175T (pt) 2017-02-14
BRPI0711310B1 (pt) 2020-12-15
BRPI0711310A2 (pt) 2011-12-06
JP2009535385A (ja) 2009-10-01
CN102942520A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
CY2021013I1 (el) Δι-αρυλ μετα-πυριμιδινο αναστολεις κινασων
DK2350047T3 (da) p38-MAP-KINASEINHIBITORER
BRPI0922962A2 (pt) inibidores de p38 map quinase
DK2013175T5 (da) p38 Map-kinase-inhibitorer
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
CY2017012I2 (el) Αναστολεις κινασης τυροσινης bruton
HK1160129A1 (en) P38 map kinase inhibitors p38 map
BRPI0716781A2 (pt) Inibidores da quinase
DK1704145T3 (da) Selektive kinaseinhibitorer
ATE493403T1 (de) Kinaseinhibitoren
ATE479434T1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
BRPI0811212A2 (pt) Inibidores de p70 quinase
EP1893607A4 (en) CHECKPOINT KINASE INHIBITORS
ATE488505T1 (de) Kinasehemmer auf hydantoinbasis
EP2278969A4 (en) INHIBITORS OF JANUS KINASES
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2125810T3 (da) Mapk/erk-kinaseinhibitorer
DK1778686T3 (da) Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer
EP2310384A4 (en) INHIBITORS OF KINASES JANUS
DK2035385T3 (da) Inhibitorer af akt (proteinkinase B)
DK2066662T3 (da) Serinhydrolaseinhibitorer
ATE520664T1 (de) Tyrosinkinase-hemmer
GB0608837D0 (en) Inhibitors of MAP kinase
DK1713805T3 (da) Kinaseinhibitorer